Yavaş, İpek

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7524
Name Variants
Yavas, I.
Yavas, Ipek
Job Title
Email Address
ipekkyavas@gmail.com
ipek.yavas@ieu.edu.tr
Main Affiliation
15.09. Physiotherapy
Status
Current Staff
Website
ORCID ID
0000-0002-4065-9534
Scopus Author ID
57415428100
Turkish CoHE Profile ID
7C6F7FD5052DD42C
Google Scholar ID
9jOwQRQAAAAJ
WoS Researcher ID
ITT-8899-2023
Files
İpekYavaş.jpg (12.17 KB)

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
0
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
1
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

4

Citations

14

h-index

2

Go to Scopus profile
Documents

14

Citations

15

Go to WoS profile
Scholarly Output

5

Articles

3

Views / Downloads

2/8

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

0

Scopus Citation Count

0

Patents

0

Projects

0

WoS Citations per Publication

0.00

Scopus Citations per Publication

0.00

Open Access Source

2

Supervised Theses

0

JournalCount
Multiple Sclerosis Journal2
Journal of Health Policy and Outcomes Research1
Physiotherapy Research International1
Türkiye Klinikleri Sağlık Bilimleri Dergisi1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2024 - 20265
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 5 of 5
  • Thumbnail Image
    Article
    Is Disease-Modifying Therapy Use in Multiple Sclerosis a Risk Factor During the Covid-19 Pandemic? a Large Cohort Study
    (Pro Medicina Foundation, 2024) Ozakbas, S.; Baba, C.; Yavas, I.; Samadzade, U.; Ozdogar, A.T.
    Objective: This study aims to investigate the relationship between disease-modifying therapies (DMTs) used in people with MS (pwMS) and the risk of COVID-19 in-fection. Methods: This longitudinal cohort study included the MS cohort of 3402 people followed for COVID-19 infection. The whole MS cohort was interviewed at least once for information about COVID-19. A semi-structured interview was developed and performed by a team consisting of a medical doctor, nurse, and physiotherapist. Clinical information was obtained from the patient's medical records. This study was approved by the Noninvasive Research Ethics Board (Date: 08.09.2021, Decision No: 2021/25-06). Results: Of the 487 pwMS infected with COVID-19, 35 reported reinfections. The major differences regarding DMT between pwMS with and without COVID-19 infection were observed for fingolimod, ocrelizumab, and azathioprine. Forty-three (8.9%) people experienced the COVID-19 infection severely or critically; 12 (37.5%) had MS treatment with ocrelizumab. Fifty percent of pwMS who were treated in intensive care (7/14 patients) and died (3/6 patients) were being treated with ocrelizumab. As a result of regression analysis, being younger and using di-methyl fumarate, fingolimod, ocrelizumab, and cladrib-ine DMTs were the main factors associated with having COVID-19 infection group. Conclusions: Current results show that disability due to MS and increased disease duration are not risk factors for COVID-19 infection, while age is negatively associated with contracting COVID-19 infection. These results show no relationship between the MS clinic and COVID-19 in-fection. We have found that using certain DMTs in pwMS increases the risk of contracting COVID-19 infection. © 2024 PRO MEDICINA Foundation,41 Published by PRO MEDICINA Foundation.
  • Thumbnail Image
    Conference Object
    Cognitive Difficulties, Coping Strategies and Barriers to Participation in Cognitive Rehabilitation in People With Multiple Sclerosis: A Qualitative Study Across Different Disability Levels
    (Sage Publications Ltd, 2025) Karakas, Hilal; Yavas, Ipek; Gokcen, Rabia; Celik, Gozubatik; Cansiz, Melek; Ertekin, Ozge; Kahraman, Turhan
  • Thumbnail Image
    Article
    Effect of Telerehabilitation-Based Music Therapy and Motor Imagery on Pain, Autonomic Function, and Psychosocial Outcomes in People With Multiple Sclerosis: A Randomized Controlled Trial Protocol
    (Wiley, 2026) Yavas, Ipek; Kahraman, Turhan; Kazdagli, Hasan; Gozubatik-Celik, Rabia Gokcen; Karakas, Hilal; Seebacher, Barbara; Ertekin, Ozge
    Background and Purpose Chronic pain affects approximately 63% of people with multiple sclerosis (pwMS), contributing to fatigue, depression, anxiety, poor sleep, reduced quality of life, and cognitive decline. Within the biopsychosocial model, music therapy has emerged as a promising intervention to address these complex symptoms. This study aims to examine the effects of heart rate-synchronized music therapy combined with motor imagery practice on pain, autonomic and cognitive functions, and psychosocial outcomes in patients with pwMS. We hypothesize that the combined intervention will lead to greater improvements than music therapy alone or routine care. Methods A double-blind, randomized, and three-arm parallel trial will be conducted with 45 patients with pwMS experiencing chronic pain. Participants will be randomly assigned to one of three groups: (1) heart rate-synchronized music therapy combined with motor imagery, (2) heart rate-synchronized music therapy alone, or (3) a control group receiving routine care. Interventions will be delivered twice weekly for 8 weeks, with each session lasting 20-30 min. The experimental groups will receive music therapy via videoconferencing. Assessments will be conducted at baseline, post-intervention (week 8), and follow-up (week 12). The primary outcome is pain intensity. Secondary outcomes include neuropathic pain, central sensitization, heart rate variability, anxiety, depression, fatigue, sleep quality, quality of life, and cognitive function. Sample size was calculated using G*Power; HRV data will be analyzed with Kubios software. Statistical analyses will be performed using SPSS and GraphPad Prism 10. Results Following randomization, baseline data will be collected. Blinded assessors will evaluate all outcomes at follow-up points. An independent researcher will perform statistical analyses to assess changes across time and between groups. Discussion This study may provide evidence supporting a novel, non-pharmacological, and telehealth-compatible intervention for chronic pain in pwMS.
  • Thumbnail Image
    Conference Object
    Age-Related Differences in E-Health Literacy in People with Multiple Sclerosis
    (Sage Publications Ltd, 2025) Yavas, Ipek; Karakas, Hilal; Celik, Rabia Gokcen Gozubatik; Cansiz, Melek; Ertekin, Ozge; Kahraman, Turhan
  • Thumbnail Image
    Article
    Multipl Sklerozlu Bireylerde Üriner Semptomlar, Bağırsak Semptomları ve Cinsel İşlev Bozukluğunun Tedavisinde Pelvik Taban Kas Eğitimi: Geleneksel Derleme
    (2024) Kahraman, Turhan; Yavaş, İpek; Ertekin, Özge
    Multipl skleroz (MS), santral sinir sisteminin otoimmün kaynaklı nöro dejeneratif bir hastalığıdır. MS’li bireyler santral sinir sistemi tutulumuna bağlı çok çeşitli semptomlar yaşayabilmektedir. MS’li bireylerin %80’inden fazlası üriner semptomlar, %39-73’ü bağırsak semptomları ve %40-90’ı cinsel işlev bo zukluğu bildirmektedir. Aynı zamanda bu semptomlar MS’li bireyin yaşam ka litesini olumsuz yönde etkileyen bir dizi soruna yol açmaktadır. Bu semptomların tedavisinde kullanılan fizyoterapi yöntemlerinden olan pelvik taban kas eğitimi günümüzde üriner inkontinans, pelvik organ prolapsusu ve fekal inkontinans için öncelikli tercih edilen bir tedavi seçeneğidir ayrıca cinsel işlevi iyileştirmede et kili olabileceğini gösteren çalışmalar bulunmaktadır. Bu derlemenin amacı, MS’li bireylerde pelvik taban kas eğitiminin önemini ve MS’ye bağlı üriner semptom lar, bağırsak semptomları ve cinsel işlev bozukluğunun yönetimindeki yerini vur gulamaktır. MS’li bireylerde pelvik taban kas eğitimi üriner inkontinans, aşırı aktif mesane ve cinsel işlev bozukluğu tedavisinde etkili bir yöntemdir. Ayrıca pelvik taban kas eğitimi alan MS’li bireylerde yaşam kalitesi de artmaktadır. Li teratürde biofeedback eğitiminin fekal inkontinans ve konstipasyon için etkili ol duğunu gösteren çalışmalar bulunmaktadır. Çalışmalar müdahalelerini pelvik taban kas eğitimi olarak tanımlanmasa da biofeedback eğitimi pelvik taban kas eğitiminde egzersizlerin doğrulanması ve eğitimin gerçekleşmesi amacıyla kul lanılan bir yöntemdir bu nedenle de pelvik taban kas eğitiminin fekal inkonti nansı ve konstipasyonu tedavi etmede etkili bir yöntem olduğu görülmektedir. MS’li bireylerde üriner retansiyonun tedavi edilmesinde mevcut bir çalışma bu lunmasa da ümit vaat eden bir alandır ve araştırılması gerekmektedir. Ayrıca mev cut kanıtların güçlendirilmesi ve net bir tedavi protokolünün tanımlanması için metodolojik olarak kaliteli araştırmalara ihtiyaç vardır.